Prenetics Global Limited
NASDAQ:PREMedical - Diagnostics & Research
+$0.43 today
- Market cap
- $185.61M
- Beta
- 0.24
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$4.18
Volume 1.58M
Average 0.22M
PRE Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Prenetics Global LimitedNASDAQ: PRE
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization remains negative
Q1 FY2026 depreciation & amortization was $184K, compared with $0 a year earlier. Trailing-twelve-month depreciation & amortization was $3.97M. Over 3 fiscal years it compounded at -20.6% a year.
Context
- Depreciation & amortization amounted to 4.1% of revenue in FY2025, down 15.3 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly depreciation & amortization holds near $184K or moves back toward the trailing-twelve-month quarterly average of $991.5K.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 3.78M USD
- Year-over-year change
- -36.2%
- 4-year CAGR
- -15.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.78M | -36.2% |
| FY2024 | 2024-12-31 | 5.93M | -23.9% |
| FY2023 | 2023-12-31 | 7.79M | +3.3% |
| FY2022 | 2022-12-31 | 7.54M | +2.7% |
| FY2021 | 2021-12-31 | 7.35M | — |
Depreciation & Amortization vs competitors
How PRE compares with its peers on the latest reported figures
- PRE's LTM Mar 2026 depreciation & amortization of $3.97M is the 6th highest of the 11 companies compared; the peer median is $3.89M.
- Its year-over-year change of +79.9% is the highest of 11, against a peer median of +9.0%.
- Depreciation & amortization amounts to 3.5% of revenue for PRE, versus a peer median of 9.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $9.54M | +11.9% | -10.7% | 8.4% | |
| LTM Mar 2026 | $8.57M | +6.1% | -1.0% | 11.0% | |
ATLNAtlantic International Corp. | LTM Dec 2025 | $6.59M | +32.0% | +9.2% | 1.5% |
| LTM Mar 2026 | $6.56M | -25.2% | -14.4% | 19.0% | |
| LTM Mar 2026 | $4.48M | -11.7% | +24.0% | 13.9% | |
| LTM Mar 2026 | $3.97M | +79.9% | -20.6% | 3.5% | |
| LTM Mar 2026 | $3.3M | +36.1% | +28.1% | 2.2% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $2.34M | +35.9% | -25.1% | 119.9% |
| LTM Mar 2026 | $1.61M | +16.3% | +19.7% | 54.5% | |
| LTM Mar 2026 | $589K | -20.5% | +14.8% | 1.3% | |
| LTM Mar 2026 | $499.7K | -57.0% | -29.2% | 2.6% | |
| Peer median (excluding PRE) | $3.89M | +9.0% | +4.1% | 9.7% | |
Competitors are the stored peer set for PRE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 12.53M | 13.16M | 21.74M | 30.62M | 92.39M |
| Cost of Revenue | 8.93M | 9.55M | 12.91M | 15.22M | 43.6M |
| Gross Profit | 3.6M | 3.62M | 8.83M | 15.4M | 48.79M |
| Gross Margin | 28.7% | 27.5% | 40.6% | 50.3% | 52.8% |
| Research & Development | 6.39M | 5.99M | 11.66M | 10.92M | 5.13M |
| Selling, General & Admin | 53.67M | 64.08M | 49.68M | 55.37M | 79.8M |
| Operating Expenses | 60.26M | 69.64M | 60.74M | 63.54M | 86.92M |
| Depreciation & Amortization | 7.35M | 7.54M | 7.79M | 5.93M | 3.78M |
| EBITDA | (209.16M) | (218.04M) | (47.9M) | (51.57M) | (32.19M) |
| EBITDA Margin | -1668.9% | -1656.3% | -220.3% | -168.4% | -34.8% |
| Operating Income | (56.66M) | (66.02M) | (51.91M) | (48.14M) | (38.13M) |
| Operating Margin | -452.1% | -501.5% | -238.7% | -157.2% | -41.3% |
| Interest Income | 201 | 472K | 3.92M | 2.04M | 1.04M |
| Interest Expense | 42.23K | 242K | 119.66K | 203K | 241K |
| Other Income / Expenses | (159.89M) | (159.8M) | (4.76M) | (9.56M) | 1.92M |
| Income Before Tax | (216.55M) | (225.82M) | (56.67M) | (57.7M) | (36.21M) |
| Pre-Tax Margin | -1727.9% | -1715.4% | -260.6% | -188.4% | -39.2% |
| Income Tax Expense | 2.57M | (245K) | (269.36K) | (7.87M) | 34K |
| Net Income | (174.01M) | (190.45M) | (62.72M) | (46.3M) | (37.71M) |
| Net Margin | -1388.4% | -1446.8% | -288.5% | -151.2% | -40.8% |
| EPS (Basic) | (47.04) | (37.57) | (5.58) | (3.64) | (2.68) |
| EPS (Diluted) | (47.04) | (37.57) | (5.58) | (3.64) | (2.68) |
| Weighted Avg Shares | 3.7M | 5.07M | 11.25M | 12.71M | 14.05M |
| Weighted Avg Shares (Diluted) | 3.7M | 5.07M | 11.25M | 12.71M | 14.05M |
Prenetics Global Limited
NASDAQ:PRE
Intrinsic Alpha fair value
Locked
Current Price
$10.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.